X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Orchid Chemicals with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs LUPIN LTD - Comparison Results

ORCHID PHARMA LTD    Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD LUPIN LTD ORCHID PHARMA LTD/
LUPIN LTD
 
P/E (TTM) x -0.2 28.4 - View Chart
P/BV x 0.2 3.0 5.3% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 ORCHID PHARMA LTD   LUPIN LTD
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
LUPIN LTD
Mar-18
ORCHID PHARMA LTD/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs1941,465 13.2%   
Low Rs35727 4.8%   
Sales per share (Unadj.) Rs276.5349.6 79.1%  
Earnings per share (Unadj.) Rs-79.25.6 -1,425.2%  
Cash flow per share (Unadj.) Rs-43.529.6 -146.9%  
Dividends per share (Unadj.) Rs05.00 0.0%  
Dividend yield (eoy) %00.5 0.0%  
Book value per share (Unadj.) Rs53.9300.3 18.0%  
Shares outstanding (eoy) m70.45452.08 15.6%   
Bonus/Rights/Conversions ESOPESOPS-  
Price / Sales ratio x0.43.1 13.2%   
Avg P/E ratio x-1.4197.2 -0.7%  
P/CF ratio (eoy) x-2.637.1 -7.1%  
Price / Book Value ratio x2.13.6 58.2%  
Dividend payout %090.0 0.0%   
Avg Mkt Cap Rs m8,067495,502 1.6%   
No. of employees `0002.817.0 16.4%   
Total wages/salary Rs m2,52728,647 8.8%   
Avg. sales/employee Rs Th6,956.19,273.6 75.0%   
Avg. wages/employee Rs Th902.51,681.0 53.7%   
Avg. net profit/employee Rs Th-1,993.0147.4 -1,351.8%   
INCOME DATA
Net Sales Rs m19,477158,042 12.3%  
Other income Rs m4071,504 27.1%   
Total revenues Rs m19,884159,545 12.5%   
Gross profit Rs m1,10331,475 3.5%  
Depreciation Rs m2,51910,859 23.2%   
Interest Rs m5,2272,044 255.8%   
Profit before tax Rs m-6,23620,076 -31.1%   
Minority Interest Rs m20-71 -27.8%   
Prior Period Items Rs m035 0.0%   
Extraordinary Inc (Exp) Rs m511-14,644 -3.5%   
Tax Rs m-1252,885 -4.3%   
Profit after tax Rs m-5,5802,513 -222.1%  
Gross profit margin %5.719.9 28.4%  
Effective tax rate %2.014.4 14.0%   
Net profit margin %-28.71.6 -1,802.1%  
BALANCE SHEET DATA
Current assets Rs m11,014122,095 9.0%   
Current liabilities Rs m32,06050,956 62.9%   
Net working cap to sales %-108.145.0 -240.1%  
Current ratio x0.32.4 14.3%  
Inventory Days Days9585 112.2%  
Debtors Days Days34120 28.0%  
Net fixed assets Rs m29,440129,876 22.7%   
Share capital Rs m705904 77.9%   
"Free" reserves Rs m2,043134,866 1.5%   
Net worth Rs m3,800135,771 2.8%   
Long term debt Rs m9,01864,245 14.0%   
Total assets Rs m46,510263,054 17.7%  
Interest coverage x-0.210.8 -1.8%   
Debt to equity ratio x2.40.5 501.5%  
Sales to assets ratio x0.40.6 69.7%   
Return on assets %-0.81.7 -43.9%  
Return on equity %-146.91.9 -7,935.4%  
Return on capital %-3.73.7 -100.4%  
Exports to sales %37.90-   
Imports to sales %22.60-   
Exports (fob) Rs m7,378NA-   
Imports (cif) Rs m4,406NA-   
Fx inflow Rs m7,51353,141 14.1%   
Fx outflow Rs m5,64919,335 29.2%   
Net fx Rs m1,86533,807 5.5%   
CASH FLOW
From Operations Rs m1,68217,512 9.6%  
From Investments Rs m-9,860-14,073 70.1%  
From Financial Activity Rs m6,644-14,921 -44.5%  
Net Cashflow Rs m-1,535-11,482 13.4%  

Share Holding

Indian Promoters % 32.3 46.6 69.3%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 4.6 11.3 40.7%  
FIIs % 3.3 31.9 10.3%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 10.1 547.5%  
Shareholders   84,811 98,259 86.3%  
Pledged promoter(s) holding % 54.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   CIPLA  PFIZER  ALKEM LABORATORIES  SUN PHARMA  PIRAMAL ENTERPRISES  

Compare ORCHID PHARMA LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

ORCHID PHARMA LTD Announces Quarterly Results (4QFY18); Net Profit Up 50.8% (Quarterly Result Update)

Aug 24, 2018 | Updated on Aug 24, 2018

For the quarter ended March 2018, ORCHID PHARMA LTD has posted a net profit of Rs 924 m (up 50.8% YoY). Sales on the other hand came in at Rs 2 bn (down 24.0% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

LUPIN LTD 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of LUPIN LTD for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of LUPIN LTD. Also includes updates on the valuation of LUPIN LTD.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Sep 21, 2018 03:37 PM

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD - IPCA LABS COMPARISON

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS